UBX1325
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema (DME)
Conditions
Diabetic Macular Edema (DME)
Trial Timeline
Jun 25, 2021 → Apr 6, 2023
NCT ID
NCT04857996About UBX1325
UBX1325 is a phase 2 stage product being developed by Unity Biotechnology for Diabetic Macular Edema (DME). The current trial status is completed. This product is registered under clinical trial identifier NCT04857996. Target conditions include Diabetic Macular Edema (DME).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04857996 | Phase 2 | Completed |
| NCT04537884 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetic Macular Edema (DME)